Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
3 Growth Stocks That Can Be No-Brainer Buys in 2025
05:03am, Friday, 13'th Dec 2024
Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations.
European drug regulator allows Novo to include reduction of kidney disease in Ozempic label
09:20am, Thursday, 12'th Dec 2024
The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a stateme
Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion fo
Novo Nordisk: Just The Right Price (Rating Upgrade)
11:12am, Wednesday, 11'th Dec 2024
For the first time since I initiated coverage on the Danish weight loss treatments company Novo Nordisk earlier this year, it's now attractive enough to be upgraded to a Buy. Fears of a slump in its b
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
09:15am, Wednesday, 11'th Dec 2024
Novo Nordisk parent's huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
03:58am, Wednesday, 11'th Dec 2024
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo N
PFE or NVO: Which Is the Better Value Stock Right Now?
12:46pm, Monday, 09'th Dec 2024
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a bett
Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue
12:44pm, Monday, 09'th Dec 2024
The proposed buyout of contract drug manufacturer Catalent won't raise competition concerns, the European Commission said.
Novo Nordisk A/S - share repurchase programme
10:43am, Monday, 09'th Dec 2024
Bagsværd, Denmark, 9 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and C
The Zacks Analyst Blog Berkshire Hathaway, Exxon Mobil, Novo Nordisk and Universal Health Realty Income Trust
06:46am, Monday, 09'th Dec 2024
Berkshire Hathaway, Exxon Mobil, Novo Nordisk and Universal Health Realty Income Trust are included in this Analyst Blog.
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
04:59am, Monday, 09'th Dec 2024
According to a sneak peek of the data from one of Eli Lilly's (LLY 0.13%) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly pow
3 No-Brainer Growth Stocks to Buy in December
06:46am, Saturday, 07'th Dec 2024
Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisati
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
01:05pm, Friday, 06'th Dec 2024
Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
Structure CEO on the competitive landscape for oral GLP-1 drugs
06:17pm, Thursday, 05'th Dec 2024
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
